Posters

Surface ablation with 0.02% mitomycin C for retreatment after LASIK and LASEK

Poster Details

First Author: K.Kim SOUTH KOREA

Co Author(s):    T. Kim                    

Abstract Details

Purpose:

To evaluate the efficacy and safety of surface ablation with mitomycin C (MMC) for the retreatment of refractive errors following LASIK and LASEK.

Setting:

Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea

Methods:

In this retrospective clinical study at a single center, 23 eyes that had surface ablation with MMC (0.02%, 20 seconds) between 2009 and 2013 for the treatment of residual refractive errors following myopic LASIK and LASEK were evaluated. All eyes were evaluated of corneal thickness, initial refractive error, time interval to retreatment, amount of retreatment, duration of postoperative topical steroids use and at pre and 1, 3, 6, and 12 months postoperatively, of uncorrected vision, spherical equivalent and corneal haziness.

Results:

Initially corrected myopia in LASIK was -6.47±2.17D and in LASEK was -5.68±2.51D. Mean time between initial and retreatment by surface ablation was 11.88±5.59 months for LASIK and 14.07±10.10 for LASEK. Retreat amount was 1.49±0.36D after LASIK and -1.65±0.41D after LASEK. At POD 12 months, uncorrected visions were -0.061±0.886 (logMAR) for LASIK group and -0.004±0.745 (logMAR) for LASEK group and spherical equivalents were -0.55±0.56D for LASIK group and 0.36±0.33D for LASEK group. Postoperative hazes developed in 1 eye out of 8 LASIK eyes and 3 eyes out of 15 LASEK eyes which were all cleared away with 2~3 months of topical steroids postoperatively.

Conclusions:

Surface ablation with 0.02% MMC is safe and highly effective for treating myopic regression following LASIK or LASEK. Application of 0.02% MMC for 20 seconds was effective in preventing postoperative haze formation and maintaining stable vision and spherical equivalent at 12 months after retreatment.

Financial Disclosure:

NONE